$ cat ./records/gates-foundation-grand-challenges-grant-to-johns-hopkins-for-mala-2010.txt
Gates Foundation Grand Challenges Grant to Johns Hopkins for Malaria Mosquito Kill-Switch Pathogen
[RECORD.TXT] · cat --full
The Gates Foundation awarded a $100,000 Grand Challenges Explorations grant to Jason Rasgon at the Johns Hopkins Malaria Research Institute to develop a pathogen that causes malaria-transmitting Anopheles mosquitoes to die after approximately ten days — shorter than the time needed for Plasmodium parasites to mature enough to be transmitted. Because the mechanism targets the mosquito rather than the parasite, it is inherently harder for resistance to evolve than with conventional insecticides or drugs.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Funds Aeras Inhaled Tuberculosis Vaccine Delivery for Needle-Free Lung Immunity
Next →
Gates Foundation Grand Challenges Grant Funds Oxitec Self-Limiting Aedes Aegypti for Dengue and Zika
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.